Nektar Therapeutics (NKTR) Research & Development (2010 - 2026)
Nektar Therapeutics (NKTR) posted quarterly Research & Development of $35.7 million for Q1 2026, up 17.06% year-over-year from $30.5 million in Q1 2025, and up 20.09% quarter-over-quarter from $29.7 million in Q4 2025.
Nektar Therapeutics (NKTR) Research & Development (2010 - 2026) Analysis & Trends
Nektar Therapeutics' Research & Development history runs 17 years deep, the most recent figure standing at $35.7 million for Q1 2026.
- In Q1 2026, Research & Development rose 17.06% year-over-year to $35.7 million; the TTM figure through Mar 2026 stood at $122.5 million (down 1.17% YoY), while the FY2025 annual figure was $117.3 million, down 2.96% from the prior year.
- Research & Development for Q1 2026 stood at $35.7 million, up from $29.7 million in the prior quarter.
- The five-year high for Research & Development was $107.3 million in Q1 2022, with the low at $24.1 million in Q3 2023.
- The 5-year median for Research & Development is $29.9 million (2023), against an average of $35.7 million.
- The sharpest annual moves came in 2023 and 2024: Research & Development slumped 71.59% in 2023, then soared 45.54% in 2024.
- Nektar Therapeutics' Research & Development stood at $34.7 million in 2022, then declined by 13.81% to $29.9 million in 2023, then slipped by 4.0% to $28.7 million in 2024, then increased by 3.36% to $29.7 million in 2025, then advanced by 20.09% to $35.7 million in 2026.
- Business Quant data shows NKTR's Research & Development at $35.7 million in Q1 2026, $29.7 million in Q4 2025, and $27.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Nektar Therapeutics | 1.49 Bn | 919.46 Mn | 3.16 Mn | 35.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 35.68 Mn |
| Dec 31, 2025 | 29.71 Mn |
| Sep 30, 2025 | 27.25 Mn |
| Jun 30, 2025 | 29.89 Mn |
| Mar 31, 2025 | 30.48 Mn |
| Dec 31, 2024 | 28.75 Mn |
| Sep 30, 2024 | 35.03 Mn |
| Jun 30, 2024 | 29.72 Mn |
| Mar 31, 2024 | 27.41 Mn |
| Dec 31, 2023 | 29.94 Mn |
| Sep 30, 2023 | 24.07 Mn |
| Jun 30, 2023 | 29.68 Mn |
| Mar 31, 2023 | 30.47 Mn |
| Dec 31, 2022 | 34.74 Mn |
| Sep 30, 2022 | 33.59 Mn |
| Jun 30, 2022 | 42.74 Mn |
| Mar 31, 2022 | 107.25 Mn |
| Dec 31, 2021 | 99.61 Mn |
| Sep 30, 2021 | 103.74 Mn |
| Jun 30, 2021 | 101.31 Mn |